최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0610807 (2015-01-30) |
등록번호 | US-9861421 (2018-01-09) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 348 |
Compositions and formulations for use with devices and systems that enable tissue cooling, such as cryotherapy applications, for alteration and reduction of adipose tissue are described. Aspects of the technology are further directed to methods, compositions and devices that provide protection of no
Compositions and formulations for use with devices and systems that enable tissue cooling, such as cryotherapy applications, for alteration and reduction of adipose tissue are described. Aspects of the technology are further directed to methods, compositions and devices that provide protection of non-targeted cells (e.g., non-lipid-rich cells) from freeze damage during dermatological and related aesthetic procedures that require sustained exposure to cold temperatures. Further aspects of the technology include systems for enhancing sustained and/or replenishing release of cryoprotectant to a treatment site prior to and during cooling applications.
1. A system for non-invasive, transdermal removal of heat from lipid-rich cells of a subject's body, comprising: an applicator having a heat-exchanging element configured to reduce a temperature of a target region beneath the epidermis of the subject selectively to reduce the temperature of lipid-ri
1. A system for non-invasive, transdermal removal of heat from lipid-rich cells of a subject's body, comprising: an applicator having a heat-exchanging element configured to reduce a temperature of a target region beneath the epidermis of the subject selectively to reduce the temperature of lipid-rich cells in the target region from a natural body temperature to a lower temperature in the target region; anda first cryoprotectant having a viscosity greater than 10,000 centipose (cP) at 20° C. to −20° C. that is configured to lower a freezing point of non-lipid-rich cells at the target region, the first cryoprotectant including a colligatively active adjuvant configured to increase absorption of the first cryoprotectant into an epidermal layer and/or dermal layer at the target region and one or more of a solute configured to raise an effective concentration of the solute in the epidermal layer and/or dermal layer, a hydrophilic molecule, and a lipophilic molecule;wherein the first cryoprotectant protects non-lipid rich cells such that the lipid-rich cells in the target region are substantially affected while non-lipid rich cells in the target region are not substantially affected when the temperature is reduced. 2. The system of claim 1 wherein the first cryoprotectant has a freezing point in the range of −40° C. to 0° C. 3. The system of claim 1, further comprising a cryoprotectant release structure between a surface of the applicator and a skin surface at the target region, the cryoprotectant release structure configured to retain and release the first cryoprotectant between the surface of the applicator and the skin surface, wherein the first cryoprotectant release structure comprises an absorbent material, a microporous pad, and/or an adhesive configured to adhere to the skin surface, and wherein the adhesive is configured to releasably retain the first cryoprotectant release structure at the skin surface at the target region. 4. The system of claim 1, further comprising a second cryoprotectant, and a cryoprotectant release structure between a surface of the applicator and a skin surface at the target region, the cryoprotectant release structure configured to retain and release the second cryoprotectant between the surface of the applicator and the skin surface, wherein the cryoprotectant release structure comprises either an absorbent material, a microporous pad, and/or an adhesive configured to adhere to the skin surface, and wherein the adhesive is configured to releasably retain the cryoprotectant release structure at the skin surface at the target region. 5. The system of claim 4 wherein the adhesive comprises at least one of a silicone gel, a wax, a hydrocarbon resin, a terpene-phenol resin, an natural resin and a synthetic resin. 6. The system of claim 4 wherein the cryoprotectant release structure provides sustained release of the second cryoprotectant to the skin surface at the lower temperature, and wherein lipid-rich cells in the target region are affected at the lower temperature while non-lipid-rich cells proximate the cryoprotectant release structure are preserved. 7. A system for removing heat from subcutaneous lipid-rich cells of a subject having skin, comprising: a treatment unit;an applicator having a cooling unit in communication with the treatment unit;a pre-treatment composition configured to be applied to the skin to increase a permeability of the skin; anda cryoprotectant composition including a colligatively active adjuvant and a solute, the cryoprotectant composition having a viscosity greater than 10,000 cP at a temperature greater than −20° C. and is configured to be applied to the skin to permeate into the skin to lower a freezing point of non-lipid-rich cells in the skin. 8. The system of claim 7 wherein the pre-treatment composition comprises an alpha-hydroxy acid, butylene glycol, a fatty acid, d-limonene, a terpene, a terpenoid, N-methyl-2-pyrrolidone, dimethylsulphoxide, 1,3-diphenylurea, dodecyl,N,N-dimethyl-aminoacetate, ethanol, alcohol, ethyl acetate, beta-cyclodextrin, alcohol, and/or isopropyl alcohol. 9. The system of claim 7, wherein the pre-treatment composition and the cryoprotectant composition are combined into a single composition and applied together onto the skin by rubbing the single composition into the skin with an abrasive cloth. 10. The system of claim 7, wherein the pre-treatment composition is first applied to the skin and thereafter the cryoprotectant composition is applied to the skin. 11. The system of claim 7, wherein the colligatively active adjuvant is configured to increase absorption of the cryoprotectant into an epidermal layer and/or dermal layer of the skin and a solute configured to raise an effective concentration of the solute in the epidermal layer and/or dermal layer of the skin. 12. The system of claim 7, wherein the solute is configured to raise an effective concentration of the solute in the epidermal layer and/or dermal layer of the skin. 13. The system of claim 7, wherein the cryoprotectant further comprises one or more of a hydrophilic molecule and a lipophilic molecule. 14. The system of claim 1, wherein the colligatively active adjuvant is glycolic acid. 15. The system of claim 1, wherein the solute comprises one or more of a calcium salt, a potassium salt, and a magnesium salt. 16. The system of claim 1, wherein the first cryoprotectant has a viscosity that is greater than 10,000 cP at 5° C. to −15° C. 17. The system of claim 7, wherein the cryoprotectant composition has a viscosity that is greater than 10,000 cP at 5° C. to −15° C.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.